Cargando…
Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis
The global COVID-19 pandemic remains a critical public health threat, as existing vaccines and drugs appear insufficient to halt the rapid transmission. During an outbreak from May to August 2021 in Taiwan, patients with severe COVID-19 were administered NRICM102, which was a traditional Chinese med...
Autores principales: | Wei, Wen-Chi, Liaw, Chia-Ching, Tsai, Keng-Chang, Chiou, Chun-Tang, Tseng, Yu-Hwei, Chiou, Wen-Fei, Lin, Yu-Chi, Tsai, Chia-I, Lin, Chen-Shien, Lin, Chen-Sung, Liou, Kuo-Tong, Yu, I-Shing, Shen, Yuh-Chiang, Su, Yi-Chang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443660/ https://www.ncbi.nlm.nih.gov/pubmed/36064077 http://dx.doi.org/10.1016/j.phrs.2022.106424 |
Ejemplares similares
-
NRICM101 ameliorates SARS-CoV-2–S1-induced pulmonary injury in K18-hACE2 mice model
por: Wei, Wen-Chi, et al.
Publicado: (2023) -
Treating COVID-19 with NRICM101 and NRICM102 – Author’s reply
por: Lin, Sunny Jui-Shan, et al.
Publicado: (2022) -
Treating COVID-19 with NRICM101 and NRICM102 – Author’s reply 3
por: Tseng, Yu-Hwei, et al.
Publicado: (2022) -
Treating COVID-19 with NRICM101 and NRICM102 – Author’s reply 2
por: Lee, Ming-Yung, et al.
Publicado: (2022) -
The development and application of NRICM101 and NRICM102 for the treatment of COVID-19
por: Ho, Shung-Tai, et al.
Publicado: (2023)